Literature DB >> 27325312

18F-FDG PET/CT heterogeneity quantification through textural features in the era of harmonisation programs: a focus on lung cancer.

Charline Lasnon1,2,3, Mohamed Majdoub4, Brice Lavigne4, Pascal Do5, Jeannick Madelaine6, Dimitris Visvikis4, Mathieu Hatt7,8, Nicolas Aide9,10,11,12.   

Abstract

PURPOSE: Quantification of tumour heterogeneity in PET images has recently gained interest, but has been shown to be dependent on image reconstruction. This study aimed to evaluate the impact of the EANM/EARL accreditation program on selected 18F-FDG heterogeneity metrics.
METHODS: To carry out our study, we prospectively analysed 71 tumours in 60 biopsy-proven lung cancer patient acquisitions reconstructed with unfiltered point spread function (PSF) positron emission tomography (PET) images (optimised for diagnostic purposes), PSF-reconstructed images with a 7-mm Gaussian filter (PSF7) chosen to meet European Association of Nuclear Medicine (EANM) 1.0 harmonising standards, and EANM Research Ltd. (EARL)-compliant ordered subset expectation maximisation (OSEM) images. Delineation was performed with fuzzy locally adaptive Bayesian (FLAB) algorithm on PSF images and reported on PSF7 and OSEM ones, and with a 50 % standardised uptake values (SUV)max threshold (SUVmax50%) applied independently to each image. Robust and repeatable heterogeneity metrics including 1st-order [area under the curve of the cumulative histogram (CHAUC)], 2nd-order (entropy, correlation, and dissimilarity), and 3rd-order [high-intensity larger area emphasis (HILAE) and zone percentage (ZP)] textural features (TF) were statistically compared.
RESULTS: Volumes obtained with SUVmax50% were significantly smaller than FLAB-derived ones, and were significantly smaller in PSF images compared to OSEM and PSF7 images. PSF-reconstructed images showed significantly higher SUVmax and SUVmean values, as well as heterogeneity for CHAUC, dissimilarity, correlation, and HILAE, and a wider range of heterogeneity values than OSEM images for most of the metrics considered, especially when analysing larger tumours. Histological subtypes had no impact on TF distribution. No significant difference was observed between any of the considered metrics (SUV or heterogeneity features) that we extracted from OSEM and PSF7 reconstructions. Furthermore, the distributions of TF for OSEM and PSF7 reconstructions according to tumour volumes were similar for all ranges of volumes.
CONCLUSION: PSF reconstruction with Gaussian filtering chosen to meet harmonising standards resulted in similar SUV values and heterogeneity information as compared to OSEM images, which validates its use within the harmonisation strategy context. However, unfiltered PSF-reconstructed images also showed higher heterogeneity according to some metrics, as well as a wider range of heterogeneity values than OSEM images for most of the metrics considered, especially when analysing larger tumours. This suggests that, whenever available, unfiltered PSF images should also be exploited to obtain the most discriminative quantitative heterogeneity features.

Entities:  

Keywords:  EARL accreditation program; FDG PET/CT; Harmonisation; Heterogeneity; Lung cancer; Quantification

Mesh:

Substances:

Year:  2016        PMID: 27325312     DOI: 10.1007/s00259-016-3441-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  40 in total

1.  Impact of Image Reconstruction Settings on Texture Features in 18F-FDG PET.

Authors:  Jianhua Yan; Jason Lim Chu-Shern; Hoi Yin Loi; Lih Kin Khor; Arvind K Sinha; Swee Tian Quek; Ivan W K Tham; David Townsend
Journal:  J Nucl Med       Date:  2015-07-30       Impact factor: 10.057

Review 2.  Standards for PET image acquisition and quantitative data analysis.

Authors:  Ronald Boellaard
Journal:  J Nucl Med       Date:  2009-04-20       Impact factor: 10.057

3.  Methodological aspects of multicenter studies with quantitative PET.

Authors:  Ronald Boellaard
Journal:  Methods Mol Biol       Date:  2011

4.  Staging the axilla in breast cancer patients with ¹⁸F-FDG PET: how small are the metastases that we can detect with new generation clinical PET systems?

Authors:  Dimitri Bellevre; Cécile Blanc Fournier; Odile Switsers; Audrey Emmanuelle Dugué; Christelle Levy; Djelila Allouache; Cédric Desmonts; Hubert Crouet; Jean-Marc Guilloit; Jean-Michel Grellard; Nicolas Aide
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-22       Impact factor: 9.236

5.  Quantitative PET/CT scanner performance characterization based upon the society of nuclear medicine and molecular imaging clinical trials network oncology clinical simulator phantom.

Authors:  John J Sunderland; Paul E Christian
Journal:  J Nucl Med       Date:  2014-12-18       Impact factor: 10.057

6.  Impact of initial PET/CT staging in terms of clinical stage, management plan, and prognosis in 592 patients with non-small-cell lung cancer.

Authors:  Satoshi Takeuchi; Benjapa Khiewvan; Patricia S Fox; Stephen G Swisher; Eric M Rohren; Roland L Bassett; Homer A Macapinlac
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-01-18       Impact factor: 9.236

7.  Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?

Authors:  David Groheux; Mohamed Majdoub; Florent Tixier; Catherine Cheze Le Rest; Antoine Martineau; Pascal Merlet; Marc Espié; Anne de Roquancourt; Elif Hindié; Mathieu Hatt; Dimitris Visvikis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-04       Impact factor: 9.236

8.  18F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort.

Authors:  Mathieu Hatt; Mohamed Majdoub; Martin Vallières; Florent Tixier; Catherine Cheze Le Rest; David Groheux; Elif Hindié; Antoine Martineau; Olivier Pradier; Roland Hustinx; Remy Perdrisot; Remy Guillevin; Issam El Naqa; Dimitris Visvikis
Journal:  J Nucl Med       Date:  2014-12-11       Impact factor: 10.057

9.  Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.

Authors:  Carlos Caicedo; Maria Jose Garcia-Velloso; Maria Dolores Lozano; Tania Labiano; Carmen Vigil Diaz; Jose Maria Lopez-Picazo; Alfonso Gurpide; Javier J Zulueta; Javier Zulueta; Jose Angel Richter Echevarria; Jose Luis Perez Gracia
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-03       Impact factor: 9.236

10.  Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients.

Authors:  Charline Lasnon; Cédric Desmonts; Elske Quak; Radj Gervais; Pascal Do; Catherine Dubos-Arvis; Nicolas Aide
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-06       Impact factor: 9.236

View more
  17 in total

1.  Radiomics in nuclear medicine: robustness, reproducibility, standardization, and how to avoid data analysis traps and replication crisis.

Authors:  Alex Zwanenburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-06-25       Impact factor: 9.236

Review 2.  Using PET for therapy monitoring in oncological clinical trials: challenges ahead.

Authors:  C M Deroose; S Stroobants; Y Liu; L K Shankar; P Bourguet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-27       Impact factor: 9.236

Review 3.  Texture analysis of medical images for radiotherapy applications.

Authors:  Elisa Scalco; Giovanna Rizzo
Journal:  Br J Radiol       Date:  2016-11-25       Impact factor: 3.039

Review 4.  NCTN Assessment on Current Applications of Radiomics in Oncology.

Authors:  Ke Nie; Hania Al-Hallaq; X Allen Li; Stanley H Benedict; Jason W Sohn; Jean M Moran; Yong Fan; Mi Huang; Michael V Knopp; Jeff M Michalski; James Monroe; Ceferino Obcemea; Christina I Tsien; Timothy Solberg; Jackie Wu; Ping Xia; Ying Xiao; Issam El Naqa
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-01-31       Impact factor: 7.038

5.  Combining baseline TMTV and gene profiling for a better risk stratification in diffuse large B cell lymphoma.

Authors:  Nicolas Aide; Charline Lasnon; Gandhi Damaj
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-17       Impact factor: 9.236

6.  Metabolic tumor burden quantified on [18F]FDG PET/CT improves TNM staging of lung cancer patients.

Authors:  Paula Lapa; Bárbara Oliveiros; Margarida Marques; Jorge Isidoro; Filipe Caseiro Alves; J M Nascimento Costa; Gracinda Costa; João Pedroso de Lima
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-07       Impact factor: 9.236

7.  EANM guideline on the role of 2-[18F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA).

Authors:  Roberto C Delgado Bolton; Nicolas Aide; Patrick M Colletti; Annamaria Ferrero; Diana Paez; Andrea Skanjeti; Francesco Giammarile
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-07-03       Impact factor: 9.236

8.  Experimental Multicenter and Multivendor Evaluation of the Performance of PET Radiomic Features Using 3-Dimensionally Printed Phantom Inserts.

Authors:  Elisabeth Pfaehler; Joyce van Sluis; Bram B J Merema; Peter van Ooijen; Ralph C M Berendsen; Floris H P van Velden; Ronald Boellaard
Journal:  J Nucl Med       Date:  2019-08-16       Impact factor: 11.082

Review 9.  Introduction to Radiomics.

Authors:  Marius E Mayerhoefer; Andrzej Materka; Georg Langs; Ida Häggström; Piotr Szczypiński; Peter Gibbs; Gary Cook
Journal:  J Nucl Med       Date:  2020-02-14       Impact factor: 11.082

Review 10.  EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies.

Authors:  Nicolas Aide; Charline Lasnon; Patrick Veit-Haibach; Terez Sera; Bernhard Sattler; Ronald Boellaard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-16       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.